Directory | Contact | Careers | Intranet | Home

Research Focus

Focusing on the interplay between host factors and viruses

The research in my laboratory mainly focuses on the interplay between host factors and two prime human threats – the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). More than 33 million people are living with HIV and approximately 2.5 million people are newly infected per year. An estimated 170 million people worldwide are chronically infected with HCV and more than 350,000 people die from HCV-related liver diseases each year. In the absence of vaccine for both HIV and HCV, there is an urgent need to develop new antiviral therapies to treat people, who are already infected, or to develop new approaches to interrupt viral transmission. A main goal in our laboratory is to identify host factors critical for HIV or HCV replication and to exploit them as targets for the development of novel antiviral therapies.

Selected References

Gallay, P.A. Cyclophilin inhibitors: a novel class of promising host targeting anti-HCV agents. Immunologic Research. In press, 2011.

de Witte, L., Bobardt, M.D, Chatterji, U., van Loenen, F.B., Verjans, G.M., Geijtenbeek, T.B.H. and Gallay, P.A. HSV Neutralization by the Microbicidal Candidate C5A. PLoS One, 6(5):e18917, 2011.

Chatterji, U., Bobardt, M.D., Lim, P., Gallay, P.A. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J. Gen. Virol. 91:1189-93, 2010.

Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., Parkinson, T., and Gallay, P.A. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol., 53:50-6, 2010.

Bobardt, M.D., Chatterji, U., Schaffer, L., de Witte, L., and Gallay, P.A. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrobial Agents and Chemotherapy, 54:2753-66, 2010.

Gallay, P.A. Cyclophilin inhibitors. Clin. Liver Dis. 13:403-17, 2009.

Chatterji, U., Bobardt, M., Selvarajah, S., Yang,F., Tang, H. Sakamoto, N Vuagniaux, G., Parkinson, T., and Gallay, P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284:16998-7005, 2009.

Bobardt, M., Cheng, G., de Witte, L., Selvarajah, S., Chatterji, U., Beer, B., Geijtenbeek, T. B. H., Chisari, F. V., and Gallay, P. A. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 105: 5525-30, 2008.

de Witte, L., Bobardt, M.D., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and Gallay, P. A. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. 104: 19464-9, 2007.